Heart Valve Disease in China
Overview
Heart valve disease means one or more of the four valves — aortic, mitral, tricuspid or pulmonary — fail to open fully (stenosis) or close properly (regurgitation), placing progressive strain on the heart. Timely repair or replacement prevents irreversible muscle damage and heart failure.
Chinese structural heart programs are among the world’s highest-volume TAVR centers, with extensive experience in transcatheter and robotic approaches that avoid open-chest surgery for patients previously considered inoperable.
Symptoms & Signs
Breathlessness on exertion, progressing to breathlessness at rest and orthopnea
Fatigue, palpitations and reduced exercise capacity
Ankle swelling and weight gain from fluid retention in advanced disease
Fainting or near-fainting episodes, characteristically in severe aortic stenosis
Often first detected as a heart murmur on routine examination before symptoms develop
Complications of untreated disease: atrial fibrillation, pulmonary hypertension and heart failure
Diagnosis
Transthoracic echocardiography — the primary tool defining valve anatomy, severity and heart function
Transesophageal and 3D echocardiography for detailed valve anatomy and procedural planning
ECG-gated cardiac CT sizing valves and access vessels for transcatheter procedures
Cardiac catheterization and coronary angiography to exclude coexisting CAD before surgery
Heart-team assessment combining cardiologists, surgeons and imaging specialists to choose the optimal approach
Exercise testing to unmask symptoms in seemingly asymptomatic severe stenosis
Treatment Options
Valve repair — the preferred approach for suitable mitral and tricuspid disease, preserving native tissue
Valve replacement with mechanical valves (lifelong durability) or bioprosthetic tissue valves (no long-term anticoagulation)
Minimally invasive and robotic surgical approaches avoiding full sternotomy, with faster recovery
TAVR/TAVI transcatheter aortic valve replacement for aortic stenosis, including in frail and high-risk patients
Transcatheter edge-to-edge repair (MitraClip-class) for mitral regurgitation in patients unfit for surgery
Anticoagulation and rhythm management programs for patients in atrial fibrillation
Advanced Technologies & Novel Drug
Latest-generation TAVR valves with lower delivery profiles and cerebral embolic protection
MitraClip-class transcatheter edge-to-edge repair systems
3D echocardiography and CT fusion imaging planning software
Robotic and rapid-deployment surgical valve platforms shortening operative time
Novel oral anticoagulants and heart-failure medications (ARNI, SGLT2 inhibitors) optimizing medical therapy around procedures
Hospital & Specialist
- Fuwai Hospital, Chinese Academy of Medical Sciences (Fuwai Hospital, CAMS & PUMC) — Beijing
- Zhongshan Hospital, Fudan University — Shanghai
- Tianjin Medical University General Hospital — Tianjin
- The Second Hospital of Tianjin Medical University — Tianjin
- Fang Quan — Cardiology
- Ni Chao — Cardiology
- Xu Jing — Cardiology
- Li Jian Hua — Cardiac Surgery